About Adgero Biopharma
Adgero Biopharma is a company based in Princeton (United States) founded in 2012 was acquired by DelMar Pharmaceuticals in June 2020.. Adgero Biopharma has raised $5.52 million across 5 funding rounds from investors including HHS, Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co and DelMar Pharmaceuticals. Adgero Biopharma operates in a competitive market with competitors including PhotoPharmics, CranioVation, Lumeda, Illumi Medical and SpectraCure, among others.
- Headquarter Princeton, United States
-
Sectors
HealthcareTechnology
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$5.52 M (USD)
in 5 rounds
-
Latest Funding Round
$225 K (USD), Grant
Jul 17, 2020
-
Investors
HHS
& 2 more
-
Employee Count
Employee Count
-
Acquired by
DelMar Pharmaceuticals
(Jun 10, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Adgero Biopharma
Adgero Biopharma has successfully raised a total of $5.52M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $225 thousand completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Grant — $225,000
-
First Round
First Round
(23 Nov 2015)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2020 | Amount | Grant - Adgero Biopharma | Valuation |
investors |
|
| Feb, 2017 | Amount | Series A - Adgero Biopharma | Valuation |
investors |
|
| Sep, 2016 | Amount | Series A - Adgero Biopharma | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Adgero Biopharma
Adgero Biopharma has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include HHS, Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co and DelMar Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
Photosensitizers and nano-formulations for cancer treatments are developed.
|
Founded Year | Domain | Location | |
|
Drug candidates targeting orphan cancer indications are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Adgero Biopharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Adgero Biopharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Adgero Biopharma Comparisons
Competitors of Adgero Biopharma
Adgero Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PhotoPharmics, CranioVation, Lumeda, Illumi Medical and SpectraCure, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Non-invasive phototherapy for Parkinson's disease is developed.
|
|
| domain | founded_year | HQ Location |
Minimally invasive devices for brain tumor treatment are provided.
|
|
| domain | founded_year | HQ Location |
Photodynamic therapy device for lung cancer treatment is developed.
|
|
| domain | founded_year | HQ Location |
Photodynamic therapy devices for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Developer of Interstitial photo dynamic therapy for solid tumours
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Adgero Biopharma
Frequently Asked Questions about Adgero Biopharma
When was Adgero Biopharma founded?
Adgero Biopharma was founded in 2012 and raised its 1st funding round 3 years after it was founded.
Where is Adgero Biopharma located?
Adgero Biopharma is headquartered in Princeton, United States. It is registered at Princeton, New Jersey, United States.
Is Adgero Biopharma a funded company?
Adgero Biopharma is a funded company, having raised a total of $5.52M across 5 funding rounds to date. The company's 1st funding round was a Series A of $459K, raised on Nov 23, 2015.
What does Adgero Biopharma do?
Adgero Biopharma was founded in 2012 in Princeton, United States, within the biopharmaceutical sector. Focus is placed on advancing photodynamic therapy for patients with cutaneous metastatic breast cancer. The treatment system incorporates a laser light source, a light delivery device, and the drug Rostaporfin. Operations center on developing and refining this therapy to address unmet needs in oncology care.
Who are the top competitors of Adgero Biopharma?
Adgero Biopharma's top competitors include PhotoPharmics, ImPact Biotech and CranioVation.
Who are Adgero Biopharma's investors?
Adgero Biopharma has 3 investors. Key investors include HHS, Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co, and DelMar Pharmaceuticals.